Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 49.
Insiders At Xenon Pharmaceuticals Sold US$1.6m In Stock, Alluding To Potential Weakness
Xenon Pharmaceuticals Appoints New COO
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Express News | Xenon Pharmaceuticals Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Express News | Xenon Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $54 From $56
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Express News | Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $49 From $50
Xenon Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Xenon Pharma GAAP EPS of -$0.75 Misses by $0.04
Express News | Xenon Pharmaceuticals Q2 Pretax Profit USD -58.257 Million Vs. IBES Estimate USD -53.8 Million
Express News | Xenon Pharmaceuticals Q2 Net Income USD -57.924 Million Vs. IBES Estimate USD -54.5 Million
Express News | Xenon Reports Q2 2024 Financial Results and Business Update
Express News | Xenon Pharmaceuticals Q2 Income From Operations USD -69.104 Million
Xenon Pharmaceuticals 2Q Loss/Shr 75c >XENE